UBS Group AG has reduced its stake in Renalytix PLC, bringing its holdings below 5% of voting rights, which exempts it from reporting obligations. This change, effective November 22, 2024, indicates strategic adjustments in UBS’s investment portfolio and may influence investor perceptions of Renalytix’s stock value. Investors are advised to monitor these developments closely as they could impact the company's market dynamics.